Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISULFIRAM vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Alcohol dependence (FDA-approved),Off-label: Cocaine dependence (limited evidence)
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Approximately 7–10 hours for parent drug; however, the disulfiram-ethanol reaction can persist up to 14 days due to irreversible inhibition of aldehyde dehydrogenase (ALDH) and slow regeneration of the enzyme. The active metabolite, diethyldithiocarbamate, has a half-life of about 15 hours.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Disulfiram is rapidly metabolized in the liver to diethyldithiocarbamate, which is further metabolized; it is primarily excreted in urine and feces.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily renal as metabolites; approximately 80% of a dose is excreted in urine as glucuronide conjugates and other metabolites, with less than 20% excreted in feces via bile. A small amount is eliminated unchanged in urine.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Approximately 96% bound primarily to albumin and also to lipoproteins.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Approximately 2–4 L/kg, indicating extensive tissue distribution and accumulation, particularly in adipose tissue due to lipophilicity.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Rapidly and almost completely absorbed after oral administration; absolute bioavailability is approximately 70–90% due to first-pass metabolism in the liver. No parenteral forms are approved; only oral route (tablets) is used clinically.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
No dose adjustment required for renal impairment; no specific GFR-based guidelines exist; use with caution in severe renal impairment.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment, but monitor liver function. Not recommended in active liver disease.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not recommended for use in patients under 18 years due to lack of established safety and efficacy.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Initiate at lower dose (125 mg/day) due to age-related decreased function; monitor closely for adverse effects.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Disulfiram should never be administered to a patient who is in a state of alcohol intoxication or without the patient's full knowledge and consent. The patient must be fully informed of the disulfiram-alcohol reaction.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Hepatotoxicity including hepatitis and hepatic failure; peripheral neuropathy; optic neuritis; psychotic reactions; hypersensitivity; risk of severe disulfiram-alcohol reaction if alcohol is consumed.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Concurrent use of alcohol or alcohol-containing preparations; metronidazole; paraldehyde; severe myocardial disease; coronary occlusion; psychosis; severe hepatic impairment; hypersensitivity to disulfiram or other thiuram derivatives.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Avoid foods and products containing alcohol: sauces (e.g., wine sauces, beer batter), vinegar (especially red/white wine vinegar), marinades, ripe fruits (fermentation can produce trace alcohol), some desserts (e.g., tiramisu, fruitcakes), alcohol-infused chocolates, non-alcoholic beer/wine (may contain up to 0.5% alcohol). Also avoid mouthwashes, breath sprays, and hand sanitizers with ethanol. Some medications like paraldehyde, chloral hydrate, and metronidazole may cross-react. Even alcohol in cooking may not fully evaporate and can trigger a reaction.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: No specific malformation patterns reported; however, theoretical risk of disulfiram-ethanol reaction causing fetal hypoxia due to maternal acetaldehyde accumulation. Use only if essential and with strict alcohol avoidance.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Excreted into breast milk in small amounts (M/P ratio not established). No adverse effects reported in nursing infants. However, theoretical risk of disulfiram-ethanol reaction if mother consumes alcohol. Recommend caution and discuss with healthcare provider; generally consider compatible with breastfeeding if mother abstains from alcohol.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No specific dose adjustment recommended in pregnancy. Pharmacokinetic studies in pregnancy not available. Use lowest effective dose (typically 250 mg/day) to minimize risks. Avoid higher loading doses. Discontinue if signs of hepatotoxicity occur.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to severe nausea, vomiting, hypotension, and flushing. Avoid use in patients with severe heart disease, psychosis, or cirrhosis. Monitor LFTs and CBC at baseline and periodically. Disulfiram may also inhibit CYP450 enzymes (CYP2E1, CYP1A2, CYP3A4), potentiating warfarin, phenytoin, and theophylline. Onset of aversion therapy requires 12-48 hours after the last alcohol dose; maintain alcohol-free period of 24 hours before starting. Duration of action persists up to 14 days after discontinuation. Inadvertent alcohol exposure in topical products (mouthwash, colognes) can trigger reactions.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Avoid all forms of alcohol, including beverages, mouthwash, cough syrup, cooking wine, vinegar, aftershave, and hand sanitizers.,Reaction to alcohol includes severe flushing, nausea, vomiting, chest pain, difficulty breathing, and blurred vision; seek emergency care if symptoms occur.,The disulfiram-alcohol reaction can be fatal even with small amounts of alcohol.,Inform all healthcare providers (including dentists) that you are taking disulfiram.,Reactions may occur up to 14 days after stopping the medication.,Do not take disulfiram if you have recently consumed alcohol; wait at least 12 hours after the last drink.,Carry a medical alert card or wear a bracelet stating you are on disulfiram.,Report any signs of liver toxicity: yellowing of eyes/skin, dark urine, severe fatigue.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
"Rifapentine, a potent inducer of cytochrome P450 enzymes, significantly increases the metabolism of disulfiram by inducing hepatic CYP3A4 and other metabolic pathways. This induction reduces disulfiram plasma concentrations, potentially diminishing its therapeutic efficacy in maintaining alcohol aversion. The interaction may lead to an increased risk of alcohol consumption relapse and associated clinical consequences."
"Disulfiram inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation, but also inhibits CYP3A4 and other CYP enzymes. Palbociclib is primarily metabolized by CYP3A4 and is a substrate of this enzyme. Coadministration with disulfiram can significantly increase palbociclib serum concentrations, raising the risk of dose-dependent toxicities such as neutropenia, infections, and fatigue."
"Disulfiram irreversibly inhibits aldehyde dehydrogenase and also suppresses the activity of cytochrome P450 (CYP) 2D6 and other CYP enzymes, thereby reducing the hepatic metabolism of venlafaxine. This can lead to increased plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine, elevating the risk of dose-dependent adverse effects such as hypertension, nausea, dizziness, and serotonin syndrome. Additionally, disulfiram's own metabolism may be affected, potentially increasing the severity of disulfiram-ethanol reactions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISULFIRAM vs ANEXSIA 7.5/650, answered by our medical review team.
DISULFIRAM is a Aldehyde Dehydrogenase Inhibitor that works by Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISULFIRAM and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISULFIRAM is: 250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISULFIRAM and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISULFIRAM is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: . ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.